U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H28N4O2
Molecular Weight 428.5261
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZALDARIDE

SMILES

CC4(CN1CCC(CC1)N2C(=O)NC3=C2C=CC=C3)OCC5=CC=CC=C5N6C=CC=C46

InChI

InChIKey=HTGCJAAPDHZCHL-UHFFFAOYSA-N
InChI=1S/C26H28N4O2/c1-26(24-11-6-14-29(24)22-9-4-2-7-19(22)17-32-26)18-28-15-12-20(13-16-28)30-23-10-5-3-8-21(23)27-25(30)31/h2-11,14,20H,12-13,15-18H2,1H3,(H,27,31)

HIDE SMILES / InChI

Description

Zaldaride is a calmodulin antagonist known to produce inhibition of calmodulin-dependent voltage-gated ion channels including those of Ca2 , Na , and K . Zaldaride was also observed to inhibit nicotinic acetylcholine receptor (nAChR) channel currents. Zaldaride has been studied in clinical trials as a potential treatment for travelers diarrhea.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
3
Target ID: Q14123
Gene ID: 5137.0
Gene Symbol: PDE1C
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 3.3 µM [IC50]
Inhibitor
8504
 0.81 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Phase III
665
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
378 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1650 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15039 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6349 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9522 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
30421 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7763 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
10 mg/kg single, subcutaneous
dose: 10 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18030 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, subcutaneous
dose: 30 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
90 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
90 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
35 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
35 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
60 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
10 mg/kg single, subcutaneous
dose: 10 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
60 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10784416/
30 mg/kg single, subcutaneous
dose: 30 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ZALDARIDE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg 4 times / day steady, oral
Highest studied dose|Studied dose
Dose: 20 mg, 4 times / day
Route: oral
Route: steady
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8440431/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/8440431/
Sources:
https://pubmed.ncbi.nlm.nih.gov/8440431/
20 mg 4 times / day steady, oral
Studied dose
Dose: 20 mg, 4 times / day
Route: oral
Route: steady
Dose: 20 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8562742/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/8562742/
Sources:
https://pubmed.ncbi.nlm.nih.gov/8562742/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

inducer
1087
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP19A1
429

CYP1A2
2153

CYP2C19
2057
P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP19A1
430
 inconclusive [IC50 29.8493 uM]
CYP1A2
2333
 inconclusive [IC50 30.9008 uM]
CYP3A4
2633
 no
CYP2D6
2546
 yes [IC50 1.3803 uM]
CYP3A4
2633
 yes [IC50 1.7377 uM]
CYP2C19
2141
 yes [IC50 21.8761 uM]
CYP2C9
2497
 yes [IC50 9.7717 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
The calmodulin inhibitor CGS 9343B inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.
2015-06-15
Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhea: randomized, placebo-controlled trial.
1995-08
CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.
1987-05
Patents

Patents

20150265627
2

Sample Use Guides

In Vivo Use Guide
Treatment of traveler's diarrhea: 20 mg zaldaride maleate four times per day
Route of Administration: Oral
In Vitro Use Guide
Zaldaride (CGS 9343B) inhibited Kv currents in rabbit coronary arterial smooth muscle cells in a concentration-dependent manner, with a half-maximal inhibitory concentration (IC50) value of 0.81uM.
Name Type Language
ZALDARIDE
INN   MART.   MI  
INN  
Official Name English
ZALDARIDE [MI]
Preferred Name English
ZALDARIDE [MART.]
Common Name English
zaldaride [INN]
Common Name English
(±)-1-(1-((4-METHYL-4H,6H-PYRROLO(1,2-A)(4,1)BENZOXAZEPIN-4-YL)METHYL)-4-PIPERIDYL)-2-BENZIMIDAZOLINONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C266
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
Code System Code Type Description
CAS
109826-26-8
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
SMS_ID
100000079367
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL1474352
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
FDA UNII
GH66PET6S3
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
MERCK INDEX
m11578
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID7046091
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
PUBCHEM
65909
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
NCI_THESAURUS
C66680
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
INN
6904
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
EVMPD
SUB00131MIG
Created by admin on Mon Mar 31 19:33:05 GMT 2025 , Edited by admin on Mon Mar 31 19:33:05 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ZALDARIDE
SALT/SOLVATE (PARENT)
Structure of ZALDARIDE MALEATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966